Baudax Bio Overview
Valuation check: BXRX's ROE is 69.89%, above the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow69.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for BXRX is 69.89%. That is above the Healthcare sector average of 20.86%. Investors often review this figure alongside Baudax Bio's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, BXRX currently prints 69.89% for ROE, while the sector average sits near 20.86%. That is roughly 235.1% above the sector mean. Large gaps often invite a closer look at Baudax Bio's growth, margins, and balance sheet.
Return on Equity shows how effectively Baudax Bio converts resources into returns. At 69.89%, BXRX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting BXRX's ROE (69.89%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Baudax Bio's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
